DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020973/S-32

SUPPLEMENT APPROVAL

Eisai Inc.
Attention: Amanda Goodwin
Associate Director, Global Regulatory Affairs
155 Tice Blvd.
Woodcliff Lake, NJ 07677

Dear Ms. Goodwin:

Please refer to your Supplemental New Drug Application (sNDA) dated January 15, 2013, received January 15 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for AcipHex (rabeprazole sodium) Delayed-Release Tablets, 20 mg.

We acknowledge receipt of your amendment dated March 27, 2013.

This "Prior Approval" supplemental new drug application provides for the following revisions to the package insert:

1. Full Prescribing Information: Section 7 (Drug Interaction) and Section 12.3 regarding the coadministration of rabeprazole and clopidogrel.

2. Update package insert to reflect recently approved revisions from NDA 204736 Aciphex Sprinkle approval on March 26, 2013.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling text for the package insert, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call CDR Stacy Barley, Senior Regulatory Project Manager, at (301) 796-2137.

Sincerely,

{See appended electronic signature page}

Andrew E. Mulberg, M.D., F.A.A.P., C.P.I.
Deputy Director
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANDREW E MULBERG
04/19/2013